Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors: A Prospective, Single-Arm Clinical Study

NCT07539610 is registered in ClinicalTrials.gov with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor.

NCT NCT07539610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07539610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors: A Prospective, Single-Arm Clinical Study
Lead sponsor
Institute of Hematology & Blood Diseases Hospital, China
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
November 30, 2027
Enrollment
9 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia/lymphoma, b-acute lymphoblastic leukemia